Angelini Pharma is acquiring Catalyst Pharmaceuticals in a $4.1 billion transaction, paying $31.50 per share for Catalyst’s Nasdaq‑listed stock.

The deal values Catalyst at about 3.5 billion euros and signals Angelini’s push into rare‑disease therapies, leveraging Catalyst’s specialized portfolio and commercial network.

By merging Catalyst’s expertise with its own brain‑health products, Angelini aims to broaden its therapeutic reach and strengthen its position in the niche market. The transaction underscores the growing trend of consolidation among specialty pharma firms.

The acquisition will likely boost Angelini’s revenue streams and diversify its pipeline, offering investors a clearer pathway into the expanding rare‑disease sector.